Assay of chlordiazepoxide and demoxepam in chlordiazepoxide formulations by difference spectrophotometry.
Rapid difference spectrophotometric methods for chlordiazepoxide and demoxepam in chlordiazepoxide formulations are described which overcome the nonspecificity of the official spectrophotometric assays. The procedures are based on the measurement of the difference absorbance at 269 nm of equimolar solutions of chlordiazepoxide at pH 8 and pH 3 and the difference absorbance at 263 nm of equimolar solutions of demoxepam at pH 13 and pH 8. The methods are specific for chlordiazepoxide and demoxepam in the presence of both compounds, 2-amino-5-chlorobenzophenone, certain coformulated drugs, and formulation excipients. Analyses of commercial dosage forms of chlordiazepoxide have shown the presence of demoxepam at concentrations in excess of the pharmacopoeial specifications in some aged samples.
D014151:Anti-Anxiety Agents; D001569:Benzodiazepines; D001570:Benzodiazepinones / Q000032:analysis*; D002214:Capsules; D002707:Chlordiazepoxide / Q000032:analysis*; D006863:Hydrogen-Ion Concentration; D013053:Spectrophotometry / Q000379:methods; D013607:Tablets
D014151:Anti-Anxiety Agents; D001570:Benzodiazepinones; D002214:Capsules; D013607:Tablets; D001569:Benzodiazepines; D002707:Chlordiazepoxide; C000869:demoxepam